MeSH term
Frequency | Condition_Probility | Adult | 56 | 0.0 |
Humans | 245 | 0.0 |
Male | 62 | 0.0 |
Middle Aged | 32 | 0.0 |
Reference Values | 3 | 0.0 |
Risk Factors | 5 | 0.0 |
European Continental Ancestry Group/*genetics | 4 | 1.0 |
HLA-C Antigens/classification/*genetics | 2 | 40.0 |
Research Support, Non-U.S. Gov't | 150 | 0.0 |
*Variation (Genetics) | 6 | 0.0 |
Alleles | 50 | 0.0 |
Amino Acid Sequence | 37 | 0.0 |
Base Sequence | 45 | 0.0 |
DNA, Complementary | 3 | 0.0 |
Female | 70 | 0.0 |
HLA-C Antigens/*genetics | 28 | 41.0 |
Molecular Sequence Data | 53 | 0.0 |
Research Support, U.S. Gov't, P.H.S. | 53 | 0.0 |
Antibody Specificity | 6 | 0.0 |
Comparative Study | 36 | 0.0 |
*Genes, MHC Class I | 20 | 7.0 |
HLA Antigens/*genetics/immunology | 2 | 4.0 |
HLA-A Antigens/genetics | 10 | 6.0 |
HLA-B Antigens/genetics | 12 | 5.0 |
HLA-C Antigens/genetics | 21 | 21.0 |
Histocompatibility Testing/*methods | 6 | 3.0 |
Polymorphism, Genetic | 19 | 0.0 |
Aged | 12 | 0.0 |
Aged, 80 and over | 3 | 0.0 |
Histocompatibility Antigens Class I/*metabolism | 4 | 4.0 |
Prospective Studies | 3 | 0.0 |
Histocompatibility Antigens Class I/immunology | 3 | 2.0 |
Killer Cells, Natural/*immunology | 18 | 3.0 |
Lymphocyte Activation | 4 | 0.0 |
Neoplasms/*immunology | 4 | 3.0 |
Age of Onset | 4 | 0.0 |
Case-Control Studies | 4 | 0.0 |
Chromosome Mapping | 19 | 0.0 |
Exons | 4 | 0.0 |
Genetic Predisposition to Disease/genetics | 2 | 0.0 |
Genotype | 19 | 0.0 |
Glycoproteins/genetics | 2 | 2.0 |
Haplotypes | 21 | 0.0 |
Linkage Disequilibrium | 5 | 0.0 |
Pedigree | 11 | 0.0 |
Proteins/*genetics | 4 | 0.0 |
Variation (Genetics) | 2 | 0.0 |
*Alleles | 14 | 1.0 |
*Gene Frequency | 5 | 0.0 |
*Genetics, Population | 2 | 0.0 |
HLA Antigens/*genetics | 23 | 2.0 |
*Linkage Disequilibrium | 4 | 2.0 |
Immunity, Cellular | 5 | 0.0 |
Lymphocytes/immunology | 2 | 0.0 |
Pregnancy | 11 | 0.0 |
Trophoblasts/immunology | 2 | 6.0 |
Cell Line | 30 | 0.0 |
Flow Cytometry | 13 | 0.0 |
HLA-C Antigens/*biosynthesis/genetics | 2 | 66.0 |
Up-Regulation | 2 | 0.0 |
Biological Transport | 2 | 0.0 |
Killer Cells, Natural/*metabolism | 6 | 10.0 |
Chromosomes, Human, Pair 6/*genetics | 2 | 1.0 |
European Continental Ancestry Group/genetics | 2 | 0.0 |
Gene Frequency/genetics | 2 | 0.0 |
HLA-DR Antigens/genetics | 9 | 2.0 |
Microsatellite Repeats/*genetics | 2 | 0.0 |
Odds Ratio | 2 | 0.0 |
Polymerase Chain Reaction | 18 | 0.0 |
Polymorphism, Genetic/genetics | 2 | 0.0 |
Tumor Necrosis Factor-alpha/*genetics | 2 | 0.0 |
HLA Antigens/*genetics/*immunology | 3 | 50.0 |
HLA-B Antigens/genetics/immunology | 3 | 12.0 |
HLA-C Antigens/genetics/immunology | 2 | 14.0 |
HLA-DQ Antigens/genetics/immunology | 2 | 10.0 |
Research Support, U.S. Gov't, Non-P.H.S. | 9 | 0.0 |
Exons/genetics | 2 | 0.0 |
Acute Disease | 3 | 0.0 |
*HLA-C Antigens | 2 | 14.0 |
HLA-DR Antigens | 3 | 0.0 |
Histocompatibility Testing | 20 | 2.0 |
In Vitro | 4 | 0.0 |
Isoantigens | 2 | 7.0 |
T-Lymphocytes, Cytotoxic/*immunology | 5 | 0.0 |
Tissue Donors | 4 | 1.0 |
HLA-B Antigens/*genetics | 12 | 4.0 |
Histocompatibility Testing/methods | 2 | 4.0 |
Immunophenotyping | 4 | 0.0 |
HLA-A Antigens/genetics/*immunology | 2 | 15.0 |
HLA-B Antigens/genetics/*immunology | 5 | 26.0 |
HLA-C Antigens/genetics/*immunology | 9 | 81.0 |
Cytotoxicity Tests, Immunologic | 6 | 1.0 |
HLA-C Antigens/immunology | 4 | 19.0 |
Tumor Cells, Cultured | 11 | 0.0 |
*Chromosomes, Human, Pair 6 | 4 | 1.0 |
Genetic Predisposition to Disease | 9 | 0.0 |
Proteins/genetics | 3 | 0.0 |
Psoriasis/*genetics | 10 | 16.0 |
Adolescent | 24 | 0.0 |
Child | 17 | 0.0 |
Conserved Sequence | 2 | 0.0 |
Animals | 25 | 0.0 |
*Evolution, Molecular | 5 | 1.0 |
Gene Frequency | 22 | 0.0 |
Mexico | 2 | 2.0 |
Immunohistochemistry | 3 | 0.0 |
K562 Cells | 2 | 0.0 |
Graft Survival | 2 | 0.0 |
HLA-B Antigens/analysis | 5 | 4.0 |
*Histocompatibility Testing | 6 | 2.0 |
Kidney Transplantation/*immunology | 2 | 0.0 |
Retrospective Studies | 2 | 0.0 |
Survival Analysis | 3 | 0.0 |
Spain | 3 | 0.0 |
Transcription Factors/*genetics | 2 | 0.0 |
Cell Line, Transformed | 9 | 0.0 |
Choriocarcinoma | 2 | 5.0 |
HLA Antigens/biosynthesis | 3 | 20.0 |
Transfection | 16 | 0.0 |
Gene Frequency/*genetics | 2 | 1.0 |
HLA-A Antigens/*genetics | 4 | 2.0 |
HLA-DQ Antigens/*genetics | 2 | 0.0 |
HLA-DR Antigens/*genetics | 2 | 0.0 |
Indians, South American/*genetics | 2 | 3.0 |
Phenotype | 11 | 0.0 |
Electrophoresis, Agar Gel | 3 | 0.0 |
Polymerase Chain Reaction/methods | 8 | 0.0 |
*Polymorphism, Genetic | 9 | 0.0 |
Down-Regulation | 2 | 0.0 |
Endoplasmic Reticulum/metabolism | 2 | 0.0 |
Protein Binding | 7 | 0.0 |
Electrophoresis, Polyacrylamide Gel | 4 | 0.0 |
Interferon Type II/pharmacology | 3 | 0.0 |
Killer Cells, Natural/immunology/metabolism | 2 | 6.0 |
Trophoblasts/drug effects/*metabolism | 2 | 25.0 |
beta 2-Microglobulin/metabolism | 2 | 2.0 |
Phylogeny | 2 | 0.0 |
Cell Division | 2 | 0.0 |
Psoriasis/*genetics/immunology | 5 | 38.0 |
*Telomere | 2 | 7.0 |
Homozygote | 4 | 0.0 |
HLA-B27 Antigen/*genetics | 2 | 10.0 |
Histocompatibility Antigens Class I/genetics | 3 | 3.0 |
Tumor Necrosis Factor-alpha/genetics | 4 | 1.0 |
HLA-A Antigens/biosynthesis/genetics | 2 | 33.0 |
HLA-B Antigens/biosynthesis/genetics | 2 | 50.0 |
3T3 Cells | 2 | 0.0 |
Mice | 15 | 0.0 |
Protein Binding/genetics/immunology | 3 | 3.0 |
HLA-DQ Antigens/genetics | 4 | 1.0 |
Terminology | 2 | 1.0 |
HLA-C Antigens/*genetics/immunology | 2 | 66.0 |
*Histocompatibility Testing/methods | 2 | 16.0 |
Probability | 2 | 0.0 |
*Tissue Donors | 2 | 1.0 |
Disease Susceptibility | 7 | 0.0 |
Genetic Markers | 5 | 0.0 |
HLA Antigens/genetics/*physiology | 2 | 40.0 |
HLA-C Antigens/genetics/physiology | 2 | 100.0 |
Binding Sites/genetics/immunology | 2 | 4.0 |
Genes, MHC Class I/*immunology | 3 | 13.0 |
HLA-DP Antigens/genetics | 2 | 4.0 |
Models, Statistical | 2 | 1.0 |
Gene Deletion | 3 | 0.0 |
Major Histocompatibility Complex/*genetics | 5 | 3.0 |
Chronic Disease | 3 | 0.0 |
*Lectins, C-Type | 3 | 1.0 |
Child, Preschool | 12 | 0.0 |
*Cytotoxicity, Immunologic | 8 | 1.0 |
HLA Antigens | 4 | 3.0 |
*Hematopoietic Stem Cell Transplantation | 4 | 1.0 |
Transplantation Immunology | 2 | 3.0 |
Transplantation, Homologous | 3 | 0.0 |
Histocompatibility/*immunology | 2 | 13.0 |
Antibodies, Monoclonal/immunology | 6 | 0.0 |
HLA-A Antigens/genetics/immunology/*metabolism | 2 | 66.0 |
HLA-B Antigens/genetics/immunology/*metabolism | 3 | 100.0 |
Immunologic Surveillance | 2 | 7.0 |
Hematopoietic Stem Cells/immunology | 2 | 2.0 |
Time Factors | 2 | 0.0 |
Treatment Outcome | 5 | 0.0 |
Ethnic Groups/*genetics | 2 | 1.0 |
Genetics, Population | 2 | 0.0 |
India | 3 | 0.0 |
Genes, MHC Class I | 6 | 4.0 |
Infant | 9 | 0.0 |
Microsatellite Repeats | 3 | 0.0 |
Psoriasis/*genetics/*immunology | 4 | 50.0 |
Glycoproteins/*genetics | 2 | 1.0 |
Point Mutation | 2 | 0.0 |
Psoriasis/*genetics/pathology | 2 | 25.0 |
Genetic Diseases, Inborn | 2 | 13.0 |
Cohort Studies | 2 | 0.0 |
Histocompatibility Antigens Class I/*genetics | 10 | 3.0 |
*Major Histocompatibility Complex | 8 | 2.0 |
Reproducibility of Results | 2 | 0.0 |
Sequence Analysis, DNA/*methods | 2 | 3.0 |
HLA-A Antigens/metabolism | 2 | 15.0 |
HLA-B Antigens/metabolism | 2 | 20.0 |
Bone Marrow Transplantation/*immunology | 5 | 4.0 |
Histocompatibility Antigens Class I/*immunology | 2 | 1.0 |
Polymerase Chain Reaction/*methods | 4 | 0.0 |
Genes, MHC Class I/*genetics | 4 | 5.0 |
Recurrence | 3 | 0.0 |
Gene Conversion | 2 | 3.0 |
Recombination, Genetic | 3 | 0.0 |
Computer Simulation | 2 | 0.0 |
HLA-A Antigens/chemistry/genetics | 2 | 100.0 |
HLA-B Antigens/chemistry/genetics | 2 | 66.0 |
HLA-C Antigens/chemistry/genetics | 2 | 100.0 |
*Recombination, Genetic | 5 | 1.0 |
Behcet Syndrome/*genetics | 3 | 13.0 |
DNA/analysis | 3 | 0.0 |
DNA Primers/chemistry | 3 | 0.0 |
Japan | 3 | 0.0 |
Alanine/genetics | 2 | 1.0 |
*Chromosome Mapping | 6 | 0.0 |
DNA Primers | 4 | 0.0 |
Electrophoresis, Gel, Pulsed-Field | 2 | 0.0 |
Evolution | 3 | 0.0 |
Polymorphism, Restriction Fragment Length | 2 | 0.0 |
DNA/isolation & purification | 2 | 1.0 |
Models, Molecular | 7 | 0.0 |
Killer Cells, Natural/immunology/*metabolism | 2 | 6.0 |
Mutagenesis, Site-Directed | 2 | 0.0 |
Solubility | 2 | 0.0 |
Cell Membrane/metabolism | 2 | 0.0 |
Cells, Cultured | 5 | 0.0 |
Peptides/metabolism | 2 | 0.0 |
Mice, Transgenic | 2 | 0.0 |
Base Composition | 2 | 0.0 |
Evolution, Molecular | 3 | 0.0 |
Genome, Human | 3 | 0.0 |
Repetitive Sequences, Nucleic Acid | 2 | 0.0 |
*Genes, MHC Class II | 2 | 0.0 |
Precipitin Tests | 3 | 0.0 |
Tissue Distribution | 3 | 0.0 |
Chi-Square Distribution | 2 | 0.0 |
Thailand | 2 | 1.0 |
Blood Donors | 2 | 0.0 |
Cloning, Molecular | 10 | 0.0 |
DNA, Complementary/isolation & purification | 2 | 1.0 |
HLA-C Antigens/chemistry/genetics/*metabolism | 2 | 100.0 |
Protein Structure, Tertiary | 4 | 0.0 |
*Polymerase Chain Reaction | 2 | 0.0 |
*Sequence Analysis, DNA | 3 | 4.0 |
*Genetic Predisposition to Disease | 4 | 0.0 |
Great Britain | 2 | 0.0 |
HLA Antigens/*immunology | 6 | 2.0 |
HLA-A2 Antigen/analysis | 2 | 14.0 |
HLA-A3 Antigen/analysis | 2 | 40.0 |
HLA-C Antigens/analysis | 5 | 10.0 |
*Bone Marrow Transplantation | 2 | 0.0 |
Blotting, Northern | 5 | 0.0 |
Chromosomes, Human, Pair 6/genetics | 2 | 1.0 |
Cosmids | 2 | 0.0 |
DNA/genetics | 3 | 0.0 |
Multigene Family | 3 | 0.0 |
Restriction Mapping | 4 | 0.0 |
Sequence Analysis, DNA | 2 | 0.0 |
Sequence Homology, Nucleic Acid | 8 | 0.0 |
Binding, Competitive/immunology | 2 | 2.0 |
Mutagenesis, Site-Directed/genetics | 2 | 4.0 |
Lectins/*metabolism | 2 | 3.0 |
HLA Antigens/*metabolism | 2 | 6.0 |
HLA-C Antigens/*immunology | 4 | 28.0 |
Ligands | 6 | 0.0 |
Protein Conformation | 6 | 0.0 |
HLA Antigens/immunology | 4 | 2.0 |
T-Lymphocytes, Cytotoxic/immunology | 6 | 1.0 |
Binding Sites/genetics | 2 | 0.0 |
Codon/genetics | 2 | 0.0 |
Consensus Sequence | 3 | 0.0 |
DNA Primers/genetics | 2 | 0.0 |
HLA-C Antigens/chemistry/*genetics | 3 | 100.0 |
Clone Cells | 6 | 0.0 |
Methylation | 4 | 0.0 |
RNA, Messenger/genetics | 3 | 0.0 |
Cytotoxicity, Immunologic | 11 | 1.0 |
Protein Structure, Secondary | 2 | 0.0 |
HLA-A Antigens/immunology | 4 | 5.0 |
HLA-B Antigens/immunology | 4 | 6.0 |
Phosphorylation | 2 | 0.0 |
Receptors, Immunologic/*physiology | 3 | 1.0 |
Killer Cells, Natural/immunology | 5 | 1.0 |
Structure-Activity Relationship | 3 | 0.0 |
Antibodies, Monoclonal | 3 | 0.0 |
DNA, Complementary/genetics | 2 | 0.0 |
Macromolecular Substances | 4 | 0.0 |
Gene Expression | 2 | 0.0 |
HLA-C Antigens/metabolism | 2 | 33.0 |
Receptors, Immunologic/*metabolism | 2 | 1.0 |
Binding Sites, Antibody | 2 | 0.0 |
HLA-C Antigens/biosynthesis/*genetics | 2 | 100.0 |
Chromosome Deletion | 3 | 0.0 |
Cross Reactions | 3 | 0.0 |
*Histocompatibility | 2 | 3.0 |
Recombinant Proteins/immunology | 2 | 0.0 |
T-Lymphocytes/*immunology | 3 | 0.0 |
*Genetic Markers | 2 | 0.0 |
Cell Membrane/immunology | 2 | 0.0 |
HLA-A Antigens/biosynthesis | 2 | 22.0 |
HLA-B Antigens/biosynthesis | 2 | 20.0 |
Kinetics | 2 | 0.0 |
HLA-A Antigens | 7 | 2.0 |
HLA-B Antigens | 9 | 2.0 |
Infant, Newborn | 4 | 0.0 |
Risk | 2 | 0.0 |
Blotting, Southern | 4 | 0.0 |
HLA-B Antigens/*immunology | 2 | 3.0 |
Sequence Alignment | 2 | 0.0 |
Polymorphism, Single Nucleotide | 2 | 0.0 |
Receptors, Immunologic/*genetics | 3 | 2.0 |
Chromosomes, Human, Pair 6 | 4 | 2.0 |
DNA/*genetics | 3 | 0.0 |
Interferon-gamma, Recombinant/pharmacology | 2 | 1.0 |
Epitopes/*immunology | 2 | 0.0 |
Isoantibodies/immunology | 2 | 4.0 |
English Abstract | 6 | 0.0 |
Finland | 3 | 1.0 |
B-Lymphocytes/immunology | 7 | 0.0 |
Oligonucleotide Probes | 2 | 0.0 |
*Immunologic Tests | 2 | 28.0 |
Epitopes | 7 | 0.0 |
HLA-D Antigens/*genetics | 2 | 1.0 |
Chromosomes, Human, Pair 6/immunology | 2 | 100.0 |
HLA Antigens/analysis | 3 | 1.0 |
HLA-B Antigens/*blood | 2 | 25.0 |
B-Lymphocytes | 2 | 1.0 |
Lymphocyte Culture Test, Mixed | 7 | 1.0 |
DNA Probes | 3 | 0.0 |
HLA Antigens/genetics | 4 | 1.0 |
Nucleic Acid Hybridization | 4 | 0.0 |
Isoelectric Focusing | 2 | 0.0 |
Histocompatibility Antigens Class I/genetics/*immunology | 2 | 7.0 |
T-Lymphocytes/immunology | 3 | 0.0 |
HLA Antigens/*analysis | 13 | 3.0 |
HLA-A Antigens/analysis | 2 | 2.0 |
Antigen-Antibody Reactions | 3 | 0.0 |
HLA-C Antigens/*genetics/*immunology | 2 | 100.0 |
L Cells (Cell Line) | 2 | 0.0 |
Immunoenzyme Techniques | 3 | 0.0 |
*Genes, Structural | 2 | 0.0 |
HLA Antigens/analysis/classification | 2 | 40.0 |
DNA/genetics/isolation & purification | 2 | 0.0 |
Gene Library | 3 | 0.0 |
Genes, Structural | 2 | 0.0 |
Killer Cells, Lymphokine-Activated/immunology | 2 | 3.0 |
Antigens, CD/*physiology | 2 | 0.0 |
Binding Sites | 2 | 0.0 |
*Linkage (Genetics) | 8 | 0.0 |
Antibodies, Monoclonal/diagnostic use | 2 | 0.0 |
Choriocarcinoma/*immunology | 2 | 25.0 |
Herpesvirus 4, Human/immunology | 2 | 2.0 |
Promoter Regions (Genetics) | 2 | 0.0 |
Transcription, Genetic | 2 | 0.0 |
HLA-DQ Antigens/immunology | 2 | 5.0 |
HLA-DR Antigens/immunology | 2 | 0.0 |
Genes, MHC Class II | 2 | 0.0 |
Linkage (Genetics) | 5 | 0.0 |
HLA-DR Antigens/analysis | 2 | 0.0 |
*Immunity, Cellular | 3 | 2.0 |
HLA Antigens/*analysis/genetics | 3 | 3.0 |
HLA-C Antigens | 11 | 8.0 |
Complement 4/*genetics | 2 | 1.0 |
DNA Restriction Enzymes/diagnostic use | 2 | 5.0 |
Periodontitis/*immunology | 2 | 11.0 |
Crossing Over, Genetic | 2 | 2.0 |
*HLA-B Antigens | 2 | 3.0 |
HLA-DR3 Antigen | 2 | 5.0 |
Histocompatibility Antigens Class II/*genetics | 2 | 1.0 |
Cardiomyopathy, Hypertrophic/*genetics/immunology | 2 | 50.0 |
Histocompatibility Antigens Class II/immunology | 2 | 1.0 |
*Immunogenetics | 2 | 16.0 |
Antibody Formation | 3 | 0.0 |
Antigens, Viral/immunology | 2 | 1.0 |
*HLA Antigens | 4 | 1.0 |
beta 2-Microglobulin/immunology | 2 | 5.0 |
Histocompatibility Antigens/*analysis | 3 | 6.0 |
